vs
Biofrontera Inc.（BFRI）与林德（LIN）财务数据对比。点击上方公司名可切换其他公司
林德的季度营收约是Biofrontera Inc.的513.5倍（$8.8B vs $17.1M），Biofrontera Inc.同比增速更快（36.2% vs 8.2%），林德自由现金流更多（$898.0K vs $-2.4M），过去两年Biofrontera Inc.的营收复合增速更高（47.0% vs 3.1%）
Biofrontera Inc.是一家专注于皮肤病治疗领域的特种生物制药企业，主要研发和商业化处方类皮肤科药物，核心产品线针对光化性角化病等常见皮肤病症，主要市场覆盖美国及欧盟地区，服务皮肤科医护人员与患者。
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
BFRI vs LIN — 直观对比
营收规模更大
LIN
是对方的513.5倍
$17.1M
营收增速更快
BFRI
高出27.9%
8.2%
自由现金流更多
LIN
多$3.3M
$-2.4M
两年增速更快
BFRI
近两年复合增速
3.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $17.1M | $8.8B |
| 净利润 | $5.6M | — |
| 毛利率 | — | 48.5% |
| 营业利润率 | 26.6% | 27.8% |
| 净利率 | 33.0% | — |
| 营收同比 | 36.2% | 8.2% |
| 净利润同比 | 504.0% | — |
| 每股收益（稀释后） | $0.62 | $3.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BFRILIN
| Q1 26 | — | $8.8B | ||
| Q4 25 | $17.1M | $8.8B | ||
| Q3 25 | $7.0M | $8.6B | ||
| Q2 25 | $9.0M | $8.5B | ||
| Q1 25 | $8.6M | $8.1B | ||
| Q4 24 | $12.6M | $8.3B | ||
| Q3 24 | $9.0M | $8.4B | ||
| Q2 24 | $7.8M | $8.3B |
净利润BFRILIN
| Q1 26 | — | — | ||
| Q4 25 | $5.6M | $1.5B | ||
| Q3 25 | $-6.6M | $1.9B | ||
| Q2 25 | $-5.3M | $1.8B | ||
| Q1 25 | $-4.2M | $1.7B | ||
| Q4 24 | $-1.4M | $1.7B | ||
| Q3 24 | $-5.7M | $1.6B | ||
| Q2 24 | $-257.0K | $1.7B |
毛利率BFRILIN
| Q1 26 | — | 48.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率BFRILIN
| Q1 26 | — | 27.8% | ||
| Q4 25 | 26.6% | 23.0% | ||
| Q3 25 | -89.8% | 27.5% | ||
| Q2 25 | -56.2% | 27.7% | ||
| Q1 25 | -52.9% | 26.9% | ||
| Q4 24 | -13.6% | 27.4% | ||
| Q3 24 | -55.0% | 25.0% | ||
| Q2 24 | -64.7% | 26.4% |
净利率BFRILIN
| Q1 26 | — | — | ||
| Q4 25 | 33.0% | 17.5% | ||
| Q3 25 | -95.1% | 22.4% | ||
| Q2 25 | -59.0% | 20.8% | ||
| Q1 25 | -48.9% | 20.6% | ||
| Q4 24 | -11.1% | 20.8% | ||
| Q3 24 | -62.9% | 18.5% | ||
| Q2 24 | -3.3% | 20.1% |
每股收益（稀释后）BFRILIN
| Q1 26 | — | $3.98 | ||
| Q4 25 | $0.62 | $3.28 | ||
| Q3 25 | $-0.62 | $4.09 | ||
| Q2 25 | $-0.57 | $3.73 | ||
| Q1 25 | $-0.47 | $3.51 | ||
| Q4 24 | $0.69 | $3.61 | ||
| Q3 24 | $-0.98 | $3.22 | ||
| Q2 24 | $-0.05 | $3.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.4M | $4.0B |
| 总债务越低越好 | — | $24.7B |
| 股东权益账面价值 | $10.5M | $40.1B |
| 总资产 | $28.6M | $86.3B |
| 负债/权益比越低杠杆越低 | — | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资BFRILIN
| Q1 26 | — | $4.0B | ||
| Q4 25 | $6.4M | $5.1B | ||
| Q3 25 | $3.4M | $4.5B | ||
| Q2 25 | $7.2M | $4.8B | ||
| Q1 25 | $1.8M | $5.3B | ||
| Q4 24 | $5.9M | $4.8B | ||
| Q3 24 | $2.9M | $5.2B | ||
| Q2 24 | $4.4M | $4.6B |
总债务BFRILIN
| Q1 26 | — | $24.7B | ||
| Q4 25 | — | $20.7B | ||
| Q3 25 | — | $18.6B | ||
| Q2 25 | — | $19.7B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | — | $15.3B | ||
| Q3 24 | — | $17.5B | ||
| Q2 24 | — | $16.9B |
股东权益BFRILIN
| Q1 26 | — | $40.1B | ||
| Q4 25 | $10.5M | $38.2B | ||
| Q3 25 | $-2.6M | $38.6B | ||
| Q2 25 | $-4.7M | $38.5B | ||
| Q1 25 | $500.0K | $38.0B | ||
| Q4 24 | $4.4M | $38.1B | ||
| Q3 24 | $5.5M | $39.2B | ||
| Q2 24 | $10.9M | $38.2B |
总资产BFRILIN
| Q1 26 | — | $86.3B | ||
| Q4 25 | $28.6M | $86.8B | ||
| Q3 25 | $15.4M | $86.0B | ||
| Q2 25 | $20.1M | $86.1B | ||
| Q1 25 | $16.6M | $82.7B | ||
| Q4 24 | $22.1M | $80.1B | ||
| Q3 24 | $18.5M | $82.5B | ||
| Q2 24 | $21.6M | $80.2B |
负债/权益比BFRILIN
| Q1 26 | — | 0.62× | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4M | — |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $898.0K |
| 自由现金流率自由现金流/营收 | -13.9% | 0.0% |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | -0.42× | — |
| 过去12个月自由现金流最近4个季度 | $-13.4M | $4.2B |
8季度趋势，按日历期对齐
经营现金流BFRILIN
| Q1 26 | — | — | ||
| Q4 25 | $-2.4M | $3.0B | ||
| Q3 25 | $-3.8M | $2.9B | ||
| Q2 25 | $-3.0M | $2.2B | ||
| Q1 25 | $-4.1M | $2.2B | ||
| Q4 24 | $-1.0M | $2.8B | ||
| Q3 24 | $-1.2M | $2.7B | ||
| Q2 24 | $-4.7M | $1.9B |
自由现金流BFRILIN
| Q1 26 | — | $898.0K | ||
| Q4 25 | $-2.4M | $1.6B | ||
| Q3 25 | $-3.8M | $1.7B | ||
| Q2 25 | $-3.0M | $954.0M | ||
| Q1 25 | $-4.1M | $891.0M | ||
| Q4 24 | $-1.0M | $1.6B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | $-4.8M | $796.0M |
自由现金流率BFRILIN
| Q1 26 | — | 0.0% | ||
| Q4 25 | -13.9% | 17.9% | ||
| Q3 25 | -54.7% | 19.4% | ||
| Q2 25 | -33.7% | 11.2% | ||
| Q1 25 | -48.0% | 11.0% | ||
| Q4 24 | -8.1% | 18.8% | ||
| Q3 24 | — | 19.9% | ||
| Q2 24 | -60.8% | 9.6% |
资本支出强度BFRILIN
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 16.6% | ||
| Q3 25 | 0.0% | 14.8% | ||
| Q2 25 | 0.0% | 14.8% | ||
| Q1 25 | 0.0% | 15.7% | ||
| Q4 24 | 0.0% | 15.1% | ||
| Q3 24 | 0.0% | 12.8% | ||
| Q2 24 | 0.6% | 13.7% |
现金转化率BFRILIN
| Q1 26 | — | — | ||
| Q4 25 | -0.42× | 1.98× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.76× | ||
| Q2 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
